miR-130a-Mediated KLF3 Can Inhibit the Growth of Lung Cancer Cells

Figures & data

Table 1 Relationship Between miR-130a and the Pathological Data of NSCLC

Factors		miR-130a		χ^2 Value	P value
		Low Expression (n=25)	High Expression (n=25)
Age (years)				0.321	0.571
	≥60 years old (n=24)	13 (52.00)	11 (44.00)
	<60 years old (n=26)	12 (48.00)	14 (56.00)
Gender				1.754	0.185
	Male (n=38)	17 (68.00)	21 (84.00)
	Female (n=12)	8 (32.00)	4 (16.00)
Differentiation				0.333	0.564
	Middle+high differentiation (n=30)	16 (64.00)	14 (56.00)
	Low differentiation (n=20)	9 (36.00)	11 (44.00)
Tumor size				1.282	0.258
	≥3cm (n=24)	10 (40.00)	14 (56.00)
	<3cm (n=26)	15 (60.00)	11 (44.00)
Lymphatic metastasis				6.480	0.011
	Positive (n=25)	17 (68.00)	8 (32.00)
	Negative (n=25)	8 (32.00)	17 (68.00)
TMN staging				6.522	0.011
	I+II (n=23)	7 (28.00)	16 (64.00)
	III+VI (n=27)	18 (72.00)	9 (36.00)
Smoking history				0.222	0.637
	Smoking (n=45)	22 (88.00)	23 (92.00)
	Non-smoking (n=5)	3 (12.00)	2 (8.00)

Table 2 Prognostic Analysis of NSCLC Patients

Factors	Univariate Cox			Multivariate Cox
	P value	HR Value	95% CI	P value	HR Value	95% CI
Age (years) (≥ 60 vs < 60)	0.303	1.429	0.725–2.816
Gender (male vs Female)	0.735	0.866	0.377–1.990
Differentiation (middle+high vs low)	0.766	0.901	0.455–1.786
Tumor size (≥ 3 cm vs < 3 cm)	0.764	1.109	0.565–2.175
Lymphatic metastasis positive vs Negative)	0.005	0.371	0.184–0.746	0.024	0.438	0.249–1.137
TMN staging (I+II vs III+IV)	0.007	2.666	1.310–5.424	0.119	1.848	0.853–4.004
Smoking history (smoking vs non-smoking)	0.501	0.665	0.203–2.178
miR-130a (high vs low)	0.009	0.394	0.197–0.790	0.041	0.475	0.232–0.971

Figure 1 Expression and survival of miR-130a in NSCLC patients. (A) miR-130a is low expressed in NSCLC patients. (B) 5-year survival rate is decreased in patients with low miR-130a expression. ***P<0.001.

Figure 2 Effects of miR-130a on lung cancer cells. (A) miR-130a expression in lung cancer cell lines. (B) Expression of lung cancer cells after transfection of miR-130a-mimics/inhibit. (C) Proliferation of lung cancer cells after transfection of miR-130a-mimics/inhibit. (D) Changes of invasion ability of lung cancer cells after transfection of miR-130a-mimics/inhibit. (E) Changes of migration ability of lung cancer cells after transfection of miR-130a-mimics/inhibit. (F) Changes of apoptosis of lung cancer cells after transfection of miR-130a-mimics/inhibit. *P<0.05, **P<0.01.

Figure 3 miR-130a bound to KLF3 in a targeted manner. (A) Mutation site of miR-130a and KLF3. (B) Dual-luciferase reporter identifies a targeted binding between miR-130a and KLF3. (C) KLF3 mRNA and protein expression in lung cancer cells after transfection of miR-130a-mimics/inhibit were detected. (D) Expression of KLF3 in NSCLC patients. (E) 5-year survival of patients with high expression of KLF3. (F) Correlation analysis of miR-130a and KLF3. **P<0.01, ***P<0.001.

Figure 4 miR-130a inhibits lung cancer cell growth by targeting KLF3. (A) Proliferation of lung cancer cells after co-transfection. (B) Invasion of lung cancer cells after co-transfection. (C) Migration of lung cancer cells after co-transfection. (D) Apoptosis of lung cancer cells after co-transfection. *P<0.05, **P<0.01.

Figure 5 miR-130a inhibits lung cancer growth by KLF3. (A) Tumor volume change of nude mice within 28 days and comparison of tumor mass of nude mice after 28 days. (B) qRT-PCR detects the relative expression of miR-130a and KLF3 mRNA in tumors of nude mice after miR-130a-mimics intervention. (C) WB experiments detect the relative expression of KLF3 protein in tumors of nude mice after miR-130a-mimics intervention. The tumor mass of nude mice after 28 days was compared with that after 28 days. *P<0.05, **P<0.01.